



General Assembly

Substitute Bill No. 5032

January Session, 2011

* _____HB05032APP__042611_____*

AN ACT REQUIRING HEALTH INSURANCE COVERAGE FOR BONE MARROW TESTING.

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. (NEW) (*Effective January 1, 2012*) (a) Subject to the
2 provisions of subsection (b) of this section, each individual health
3 insurance policy providing coverage of the type specified in
4 subdivisions (1), (2), (4), (11) and (12) of section 38a-469 of the general
5 statutes delivered, issued for delivery, amended, renewed or
6 continued in this state shall provide coverage for expenses arising
7 from medically necessary human leukocyte antigen testing, also
8 referred to as histocompatibility locus antigen testing, for A, B and DR
9 antigens for utilization in bone marrow transplantation.

10 (b) No such policy shall impose a coinsurance, copayment,
11 deductible or other out-of-pocket expense for such testing in excess of
12 twenty per cent of the cost for such testing per year. The provisions of
13 this subsection shall not apply to a high deductible health plan as that
14 term is used in subsection (f) of section 38a-493 of the general statutes.

15 (c) Such policy shall:

16 (1) Require that such testing be performed in a facility (A)
17 accredited by the American Society for Histocompatibility and
18 Immunogenetics, or its successor, and (B) certified under the Clinical

19 Laboratory Improvement Act of 1967, 42 USC Section 263a, as
20 amended from time to time; and

21 (2) Limit coverage to individuals who, at the time of such testing,
22 complete and sign an informed consent form that also authorizes the
23 results of the test to be used for participation in the National Marrow
24 Donor Program.

25 (d) Such policy may limit such coverage to a lifetime maximum
26 benefit of one testing.

27 Sec. 2. (NEW) (*Effective January 1, 2012*) (a) Subject to the provisions
28 of subsection (b) of this section, each group health insurance policy
29 providing coverage of the type specified in subdivisions (1), (2), (4),
30 (11) and (12) of section 38a-469 of the general statutes delivered, issued
31 for delivery, amended, renewed or continued in this state shall provide
32 coverage for expenses arising from medically necessary human
33 leukocyte antigen testing, also referred to as histocompatibility locus
34 antigen testing, for A, B and DR antigens for utilization in bone
35 marrow transplantation.

36 (b) No such policy shall impose a coinsurance, copayment,
37 deductible or other out-of-pocket expense for such testing in excess of
38 twenty per cent of the cost for such testing per year. The provisions of
39 this subsection shall not apply to a high deductible health plan as that
40 term is used in subsection (f) of section 38a-520 of the general statutes.

41 (c) Such policy shall:

42 (1) Require that such testing be performed in a facility (A)
43 accredited by the American Society for Histocompatibility and
44 Immunogenetics, or its successor, and (B) certified under the Clinical
45 Laboratory Improvement Act of 1967, 42 USC Section 263a, as
46 amended from time to time; and

47 (2) Limit coverage to individuals who, at the time of such testing,
48 complete and sign an informed consent form that also authorizes the

49 results of the test to be used for participation in the National Marrow
50 Donor Program.

51 (d) Such policy may limit such coverage to a lifetime maximum
52 benefit of one testing.

This act shall take effect as follows and shall amend the following sections:		
Section 1	<i>January 1, 2012</i>	New section
Sec. 2	<i>January 1, 2012</i>	New section

APP *Joint Favorable Subst.*